In order to gain approval by the FDA for commercial use in the United States, a clinical study is now underway to determine the safety and effectiveness of Superion™ ISS in treating moderate lumbar spinal stenosis.

The Superion™ device will be compared to the X-STOP^® IPD^® device, which is commercially available in the United States.  Patients who meet the study criteria and agree to participate in the study are randomly chosen to receive either the X-STOP^® IPD^® or the Superion™ ISS and will be evaluated at specific follow-up visits for 24 months after their surgery.